Anzeige
Mehr »
Sonntag, 20.07.2025 - Börsentäglich über 12.000 News
Foremost Clean Energy: Auf dem Weg zu großen Entdeckungen im Saudi-Arabien des Urans
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C9EK | ISIN: US36870W1009 | Ticker-Symbol: K5F
Frankfurt
18.07.25 | 08:10
2,980 Euro
-1,97 % -0,060
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GENENTA SCIENCE SPA ADR Chart 1 Jahr
5-Tage-Chart
GENENTA SCIENCE SPA ADR 5-Tage-Chart

Aktuelle News zur GENENTA SCIENCE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
GENENTA SCIENCE Aktie jetzt für 0€ handeln
02.07.Genenta Science-Aktie behält Kaufempfehlung - Temferon vielversprechende Ergebnisse bei GBM zeigt1
02.07.Genenta Science stock maintains Buy rating as Temferon shows promise in GBM1
01.07.GENENTA SCIENCE SPA: Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals1
08.05.D.Boral Capital: Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference169Milan, Italy and New York, New York--(Newsfile Corp. - May 8, 2025) - Genenta Science, SpA (NASDAQ: GNTA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking...
► Artikel lesen
07.05.Genenta And Anemocyte Partner To Advance Immuno-Oncology Therapy Development1
15.04.GENENTA SCIENCE SPA: Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar1
28.03.Genenta Science S.p.A. - 20-F, Annual and transition report of foreign private issuers1
20.03.Italy's private debt & corporate finance weekly round-up. News from Dolce&Gabbana, Genenta Science, ENEA Tech and Biomedical, Guzzini&Fontana Projects, BdM Banca - Gruppo Mediocredito Centrale, and more2
19.03.Genenta secures $21.9 million for cancer drug trial1
19.03.GENENTA SCIENCE SPA: Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates149MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million)...
► Artikel lesen
19.03.Genenta Science S.p.A. - 6-K, Report of foreign issuer1
09.01.GENENTA SCIENCE SPA: Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing431MILAN and NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that it has strengthened...
► Artikel lesen
02.10.24GENENTA SCIENCE SPA: Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer147MILAN and NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia...
► Artikel lesen
13 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1